Cochlear (COH.AX) Stock Price
Cochlear Price
Cochlear (COH.AX) Stock | ISIN AU000000COH5 | WKN 898321. The current Cochlear stock price is 114.4 AUD (2026). Revenue is 2.47 B AUD. Net income is 418.91 M AUD. The P/E ratio is 17.92. Market capitalization is 7.51 B AUD. Cochlear operates in the Health sector.
Over the last 19 years Cochlear grew revenue by 9% annually, reaching 2.34 B AUD. Earnings per share have grown at 7.7% per year over the last 19 years. For Cochlear, the net margin of 16.6% is down versus 21.8% a few years ago. At today's price the dividend yield works out to roughly 5.09%. The payout ratio is around 72% of earnings. The dividend has grown at 7.7% per year over the past 19 years.
Cochlear stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Cochlear over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cochlear stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cochlear's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Cochlear Price |
|---|
Cochlear Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B AUD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B AUD) |
| NET INCOME (M AUD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (AUD)DIV. (AUD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 2.24 | 2.34 | 2.47 | 2.7 | 2.95 | 3.19 | 3.27 | 3.55 |
| 15.44 | 4.83 | 5.42 | 9.35 | 9.26 | 8.07 | 2.45 | 8.75 |
| 74.85 | 73.71 | 69.92 | 63.94 | 58.52 | 54.15 | 52.86 | 48.61 |
| 1.67 | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 |
| 356 | 388 | 418 | 472 | 532 | 599 | 652 | 685 |
| 18.67 | 8.99 | 7.73 | 12.92 | 12.71 | 12.59 | 8.85 | 5.06 |
| 5.42 | 5.82 | 2.93 | 5.02 | 5.75 | - | - | - |
| 33.5 | 7.38 | -49.66 | 71.33 | 14.54 | – | – | – |
| 65.72 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 | 65.61 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Cochlear generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cochlear retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cochlear's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Cochlear has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cochlear's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Cochlear stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear business model & stock analysis
Cochlear SWOT Analysis
Strengths
Cochlear Ltd possesses several key strengths that contribute to its success in the market. Firstly, the company is a pioneer and leader in the field of implantable hearing solutions, with over 30 years of experience. This enables them to offer innovative and technologically advanced products that provide significant benefits to individuals with hearing loss.
Moreover, Cochlear has established a strong global presence with a wide distribution network spanning across more than 100 countries. This allows them to reach a large customer base and maintain strong relationships with healthcare professionals, ensuring accessibility and support for their products. Additionally, the company has a robust intellectual property portfolio, providing them with a competitive advantage in the market.
Weaknesses
Despite its strengths, Cochlear Ltd faces a few weaknesses that could pose challenges. One significant weakness is the high cost associated with their implantable hearing solutions. This can limit their accessibility to a substantial portion of the population, particularly in developing countries or regions where healthcare budgets are constrained.
Another weakness lies in the complexity of the surgical procedure required for implanting their hearing devices. This could deter potential customers who might prefer less invasive options or who are reluctant to undergo surgery. Additionally, as a specialized medical device company, Cochlear relies heavily on regulatory approvals, which can lead to delays in product launches and market entry.
Opportunities
Cochlear Ltd operates in an industry with several significant opportunities. Firstly, the growing global prevalence of hearing loss, coupled with an aging population, presents a substantial market opportunity for the company. They can leverage their expertise and portfolio to address the unmet needs of individuals with hearing impairment worldwide.
Furthermore, advancements in technology and digital healthcare offer opportunities for Cochlear to develop innovative solutions that improve user experience and convenience. The increasing adoption of telehealth and remote patient monitoring also opens new avenues for Cochlear to provide virtual support and services to its customers, enhancing accessibility and convenience.
Threats
Cochlear Ltd operates in a competitive market with several threats that could impact its business. One significant threat is the presence of well-established competitors in the hearing solutions industry who have the financial resources and R&D capabilities to develop competitive products. This intensifies the need for Cochlear to maintain its focus on innovation and differentiation.
Additionally, changes in healthcare policies and reimbursement systems can pose a threat to Cochlear's financial performance. Reimbursement cuts or changes in coverage policies may affect the affordability and accessibility of the company's products, impacting market demand. Lastly, economic downturns or financial crises can also have an adverse effect on Cochlear's business, as discretionary healthcare spending may decline during such periods.
Cochlear Eulerpool Fair Value
Cochlear historical P/E ratio, EBIT multiple, and P/S ratio
Cochlear annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Cochlear shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Dividend History
31 years of dividend payments · 5 consecutive increases
Cochlear dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Cochlear Earnings Estimates
Cochlear Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 2/16/2024 | 2.6AUD | 1.04 BAUD | 2024 Q2 |
| 8/17/2023 | 2.57AUD | 960.5 MAUD | 2023 Q4 |
| 2/20/2023 | 1.92AUD | 870.52 MAUD | 2023 Q2 |
| 8/19/2022 | 1.94AUD | 846.25 MAUD | 2022 Q4 |
| 2/22/2022 | 1.99AUD | 796.42 MAUD | 2022 Q2 |
| 8/20/2021 | 1.79AUD | 733.62 MAUD | 2021 Q4 |
| 2/19/2021 | 1.46AUD | 680.43 MAUD | 2021 Q2 |
| 8/18/2020 | 0.36AUD | 518.33 MAUD | 2020 Q4 |
| 2/18/2020 | 2.53AUD | 806.91 MAUD | 2020 Q2 |
| 8/16/2019 | 2.47AUD | 774.48 MAUD | 2019 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Cochlear stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Cochlear shareholder structure
| % | Name |
|---|---|
6.18765% | |
6.07258% | |
5.99021% | |
5.33139% | |
4.86832% | |
2.52274% | |
2.02943% | |
1.76145% | |
1.56275% | |
1.29858% |
Cochlear Executives and Management Board
Mr. Diggory Howitt
(56)President, Chief Executive Officer, Executive Director
Mr. Jan Janssen
Chief Technology Officer
Mr. Stuart Sayers
President, Asia Pacific & Latin America
Mr. Anthony Bishop
President - EMEA
Ms. Alison Deans
(57)Non-Executive Independent Chairman of the Board
Frequently asked questions about Cochlear
Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.
Cochlear stock
Cochlear Peer Group
Cochlear Ticker
Cochlear FIGI
All fundamentals and in-depth analysis of Cochlear
Our stock analysis for Cochlear Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cochlear Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.